Health Economics and Quality of Life in Cancer Trials
Author Information
Author(s): R Fitzpatrick, L Davies
Primary Institution: University of Oxford; University of York
Hypothesis
When should health economics and quality of life assessments be included in cancer clinical trials?
Conclusion
Incorporating health economics and quality of life assessments into cancer trials is essential but complex, requiring careful consideration of methodology and participant burden.
Supporting Evidence
- Quality of life measures are essential for understanding the impact of cancer treatments on patients.
- Health economic evaluations can inform decisions about the value of new treatments.
- Quality of life and economic data often address distinct questions in clinical trials.
Takeaway
This study talks about how important it is to think about patients' quality of life and the costs of treatments when doing cancer research. It helps make sure that new treatments are not just effective but also good for patients.
Methodology
The paper summarizes discussions from a workshop involving clinicians, health economists, and other experts to address the integration of health economics and quality of life in cancer trials.
Potential Biases
Potential biases may arise from the subjective nature of quality of life assessments and the varying perspectives of patients and healthcare providers.
Limitations
There is no consensus on when to include quality of life and economic data in trials, and the burden of additional data collection may affect trial feasibility.
Want to read the original?
Access the complete publication on the publisher's website